Lung cancer in multi-parametric PET/MRI: assessment of subtype and EGFR status based on amide proton transfer-weighted imaging and 18F-FDG PET
Nan Meng1, Fangfang Fu2, Pengyang Feng3, Ziqiang Li4, Zhun Huang3, Ting Fang1, Yaping Wu2, Jianmin Yuan5, Yang Yang6, Hui Liu7, and Meiyun Wang*1
1Department of Medical Imaging, Zhengzhou University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou, China, 2Department of Medical Imaging, Henan Provincial People’s Hospital, Zhengzhou, China, 3Department of Medical Imaging, Henan University People’s Hospital & Henan Provincial People’s Hospital, Zhengzhou, China, 4Department of Medical Imaging, Xinxiang Medical University Henan Provincial People’s Hospital, Zhengzhou, China, 5Central Research Institute, UIH Group, Shanghai, China, 6Beijing United Imaging Research Institute of Intelligent Imaging, UIH Group, Beijing, China, 7UIH America, Houston, TX, United States
18F-Fluorodeoxyglucose positron-emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) allows multimodal quantitative MRI sequences to be scanned in parallel with PET imaging, providing a more multidimensional reflection of lesion information. Our results showed that amide proton transfer-weighted imaging (APTWI), and metabolism related parameters can be beneficial for the non-invasive assessment of subtype and EGFR status in patients with lung cancer.
This abstract and the presentation materials are available to members only;
a login is required.